A Comprehensive Overview of Cardia Cancer: Exploring a Chemotherapeutic Agent and Two Targeted Therapeutics
DOI:
https://doi.org/10.61173/9h8mzw89Keywords:
cardia cancer, chemotherapeutic agents, tar-geted therapies, pharmacologyAbstract
Cardia cancer, a subtype of gastric cancer occurring at the gastroesophageal junction, poses significant challenges due to its high malignancy, rapid progression, and tendency for metastasis and recurrence. Its development is linked to chronic gastric diseases, gastroesophageal reflux disease, and Helicobacter pylori infection. HER2 status is crucial in cardia cancer, with HER2-positive tumors benefiting from targeted therapies like Herceptin. Diagnosis relies on endoscopy, biopsy, and imaging techniques. Treatment involves chemotherapy and targeted therapies. Capecitabine, a chemotherapeutic agent, mimics continuous 5-FU infusion but with reduced gastrointestinal toxicity. It selectively accumulates in tumor tissue, inhibiting cell division by disrupting DNA and RNA synthesis. Two synthetic routes for capecitabine are described, both starting from D-ribose and utilizing distinct chemical transformations. Herceptin, a targeted therapy, binds to the HER2 receptor, inhibiting its downstream signaling pathways and promoting cell-cycle arrest and apoptosis in HER2-positive cardia cancers. However, resistance mechanisms may limit its efficacy over time. Bevacizumab targets vascular endothelial growth factor (VEGF), inhibiting angiogenesis and reducing tumor blood supply, nutrition, and metastasis. By normalizing tumor vasculature, bevacizumab enhances chemotherapy efficacy. Its use with chemotherapy regimens has shown improved survival outcomes in clinical trials. Adverse effects include hypertension, proteinuria, and gastrointestinal perforation, necessitating careful patient monitoring. In conclusion, the paper provides an overview of cardia cancer, discussing its epidemiology, diagnosis, and treatment with a focus on capecitabine as a chemotherapeutic agent and Herceptin and Bevacizumab as targeted therapies. These approaches aim to improve outcomes for patients with this aggressive subtype of gastric cancer.
References
[1] Koh, J. S., Joo, M. K., Park, J.-J., Lee, B. J., Chun, H. J., Lee, S. W., Jang, Y.-J., and Mok, Y.-J. (2019) Characteristics of proximal early gastric cancer differentiating distal early gastric cancer, PLOS ONE 14, e0223284.
[2] Seery, J. P. (1991) A reinterpretation of the events in gastric carcinogenesis, Medical Hypotheses 35, 179-181.
[3] Akiyama, T., Sudo, C., Ogawara, H., Toyoshima, K., and Yamamoto, T. (1986) The Product of the Human c-erbB-2 Gene: a 185-Kilodalton Glycoprotein with Tyrosine Kinase Activity, Science 232, 1644-1646.
[4] Gerber, D. E. (2008) Targeted therapies: a new generation of cancer treatments, American family physician 77 3, 311-319.
[5] Johnston, P. G., and Kaye, S. (2001) Capecitabine: a novel agent for the treatment of solid tumors, Anti-Cancer Drugs 12.
[6] Fei, X., Wang, J.-Q., Miller, K. D., Sledge, G. W., Hutchins, G. D., and Zheng, Q.-H. (2004) Synthesis of [18F]Xeloda as a novel potential PET radiotracer for imaging enzymes in cancers, Nuclear Medicine and Biology 31, 1033-1041.
[7] Al-Toubah, T. E., Pelle, E., Haider, M., and Strosberg, J. R. (2020) Toxicity analysis of capecitabine/temozolomide in NETs, Journal of Clinical Oncology 38, 4614-4614.
[8] Nahta, R., and Esteva, F. J. (2006) Herceptin: mechanisms of action and resistance, Cancer Letters 232, 123-138.
[9] Baselga, J., Albanell, J., Molina, M. A., and Arribas, J. (2001) Mechanism of action of trastuzumab and scientific update, Seminars in Oncology 28, 4-11.
[10] Upton, R., Bell, L., Guy, C., Caldwell, P., Estdale, S., Barran, P. E., and Firth, D. (2016) Orthogonal Assessment of Biotherapeutic Glycosylation: A Case Study Correlating N-Glycan Core Afucosylation of Herceptin with Mechanism of Action, Analytical Chemistry 88, 10259-10265.
[11] Nagata, Y., Lan, K.-H., Zhou, X., Tan, M., Esteva, F. J., Sahin, A. A., Klos, K. S., Li, P., Monia, B. P., Nguyen, N. T., Hortobagyi, G. N., Hung, M.-C., and Yu, D. (2004) PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients, Cancer Cell 6, 117-127.
[12] Varga, Z. V., Ferdinandy, P., Liaudet, L., and Pacher, P. (2015) Drug-induced mitochondrial dysfunction and cardiotoxicity, Am J Physiol Heart Circ Physiol 309, H1453- 1467.
[13] Lee, A. (2022) MYL-1402O: A Bevacizumab Biosimilar, Targeted Oncology 17, 85-88.
[14] Liu, X.-J., Zhao, H.-C., Hou, S.-J., Zhang, H.-J., Cheng, L., Yuan, S., Zhang, L.-R., Song, J., Zhang, S.-Y., and Chen, S.-W. (2023) Recent development of multi-target VEGFR-2 inhibitors for the cancer therapy, Bioorganic Chemistry 133, 106425.
[15] Lacal, P. M., and Graziani, G. (2018) Therapeutic implication of vascular endothelial growth factor receptor-1 (VEGFR-1) targeting in cancer cells and tumor microenvironment by competitive and non-competitive inhibitors, Pharmacological Research 136, 97-107.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
